ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 580

Association of Comorbidities with Disease Activity and Functional Impairment in Axial Spondyloarthritis: Results from a Nationwide Population-Based Study

Imke Redeker1, Johanna Callhoff 2, Falk Hoffmann 3, Hildrun Haibel 4, Joachim Sieper 4, Angela Zink 5 and Denis Poddubnyy 6, 1Charité – Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, 2German Rheumatism Research Centre, Berlin, Germany, 3Carl von Ossietzky University, Oldenburg, Germany, 4Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, 5German Rheumatism Research Centre and Charité University medicine, Berlin, Germany, 6Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis, Comorbidity, Disease Activity and functional status

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Data on the prevalence of comorbidities and their association with disease activity and functional impairment in axial spondyloarthritis (axSpA) are scarce. The aim of this study was to investigate the prevalence of comorbidities and to analyse their association with disease activity and functional impairment in a large population-based cohort of patients with axSpA.

Methods: A stratified random sample of patients with axSpA (ICD-10 M45) was drawn from health insurance data in Germany. Patients in the sample received a survey on demographic, socioeconomic, and disease-related parameters including disease activity (assessed using BASDAI) and functional impairment (assessed using BASFI).

Survey data were linked to health insurance data gathering additional information on comorbidities and drug prescriptions. Comorbidities were based on Elixhauser coding algorithms (excluding rheumatic diseases and augmented upon osteoporosis).

The prevalence of comorbidities in axSpA patients was compared to a sex- and age-matched control group of patients without axSpA drawn from health insurance data.

Separate multivariable linear regression models were calculated to determine the association of comorbidities with disease activity and functional impairment.

Results: A total of 1,776 patients with axSpA were included in the analyses. The patients’ main characteristics are shown in Table 1: The mean age was 56.1 years and 46.4% were female. The most prevalent comorbidities are illustrated in Figure: 52% of the patients presented with hypertension, 25% with depression, and 23% with chronic pulmonary disease. The prevalence of the majority of comorbidities was higher in axSpA as compared to controls. Results from the multivariable linear regression models are presented in Table 2 showing that the number of comorbidities was significantly associated with both disease activity and functional impairment: each comorbidity was associated with BASDAI increase by 0.11 and BASFI increase by 0.10 points independently of other factors including treatment.

Conclusion: Comorbidities are common in axSpA patients and are independently associated with higher disease activity and higher level of functional impairment. Higher disease activity and a higher level of functional disability might be indicators of a severe disease resulting in the development of comorbid conditions.


Disclosure: I. Redeker, None; J. Callhoff, None; F. Hoffmann, None; H. Haibel, AbbVie, 5, 8, Janssen, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8; J. Sieper, AbbVie, 5, 8, Eli Lilly and Company, 5, 8, Janssen, 5, 8, Lilly, 5, 8, Merck, 5, 8, Novartis, 5, 8; A. Zink, Astra Zeneca, BMS, Lilly, Pfizer, Roche und UCB, 5, 8; D. Poddubnyy, Abbvie, 2, 5, 8, AbbVie, 2, 5, 8, BMS, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Eli Lilly and Company, 2, 5, 8, Lilly, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Roche, 5, 8, UCB, 5, 8.

To cite this abstract in AMA style:

Redeker I, Callhoff J, Hoffmann F, Haibel H, Sieper J, Zink A, Poddubnyy D. Association of Comorbidities with Disease Activity and Functional Impairment in Axial Spondyloarthritis: Results from a Nationwide Population-Based Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/association-of-comorbidities-with-disease-activity-and-functional-impairment-in-axial-spondyloarthritis-results-from-a-nationwide-population-based-study/. Accessed April 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-comorbidities-with-disease-activity-and-functional-impairment-in-axial-spondyloarthritis-results-from-a-nationwide-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.